ABSTRACT
Aim: The Spontaneously Diabetic Torii (SDT) fatty rat is a metabolic syndrome model, showing obesity, hyperglycemia, dyslipidemia, and hypertension. Moreover, female SDT fatty rats exhibit hepatic steatosis. In this study, metabolic abnormalities, particularly in the liver, were assessed in male SDT fatty rats fed a diet containing 40% fat and 2% cholesterol (HFC-diet). Location and Duration of Study: Niigata University, CLEA Japan and JT Central Pharmaceutical Research Institute, between January and December 2014. Methodology: Male SDT fatty rats in control and HFC groups were fed a standard or HFC-diet (40% fat and 2% cholesterol, based on percentage of total calories) from 5 to 17 weeks of age, respectively. Body weight and blood chemistry parameters were periodically measured and a pathological analysis of the liver was performed at 17 weeks of age. Results: In biological analyses, the HFC group showed increases in body weight, blood insulin, and total cholesterol during the experimental period and an increase in aspartate aminotransferase (AST) at 13 weeks of age. Blood glucose levels in HFC group decreased after 13 weeks of age. In pathological examinations, an increase in liver weight and hepatic steatosis, fatty change and hypertrophy in hepatocyte, were observed in the HFC group. Hepatic steatosis was not observed in the standard-diet group. Conclusion: Male SDT fatty rats fed an HFC-diet may serve as a new nonalcoholic fatty liver disease (NAFLD) model.
ABSTRACT
Aim: This study was conducted to investigate the preventive or therapeutic effect of α- glucosidase inhibitor voglibose in a new model rat, Spontaneously Diabetic Torii-Leprfa (SDT fatty) rat, which is a novel type 2 diabetic rat showing obesity, hyperglycemia and hyperlipidemia from a young age. Place and Duration of Study: Niigata University and JT Central Pharmaceutical Research Institute, between January and August 2011. Methodology: The present study was designed to the preventive and therapeutic effect of voglibose by administering (0.3, 1 mg/kg) voglibose as a dietary admixture to SDT fatty rats from 5 to 11 and 14 to 20 weeks of age, respectively. Results: In the examination of preventive effect, the obtained biochemical results show that voglibose decrease glucose level significantly in dose-dependent manner within 5-11 weeks of age. In voglibose-treated rats at 11 weeks of age, the histopathological pancreatic changes, such as vacuolation and irregular boundaries in islets, were improved. On the other hand, in the examination of therapeutic effect, voglibose improved the hyperglycemia only at a dose of 1 mg/kg within 16-20 weeks of age. Conclusion: Voglibose showed both preventive and therapeutic effects for diabetes in female SDT fatty rats. The SDT fatty rat is a useful model for development of anti-diabetic agents.